Global Muscle Invasive Bladder Cancer Pipeline Insight Report 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Muscle Invasive Bladder cancer- Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

A detailed picture of the Muscle Invasive Bladder cancer pipeline landscape is provided which includes the disease overview and Muscle Invasive Bladder cancer treatment guidelines.

The assessment part of the report embraces, in depth Muscle Invasive Bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle Invasive Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Muscle Invasive Bladder cancer Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Muscle Invasive Bladder cancer targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Muscle Invasive Bladder cancer pipeline report covers 5+ companies. Some of the key players include Taris Bio (TAR-200), AstraZeneca (Durvalumab) etc.

Scope of the report

  • The Muscle Invasive Bladder cancer report provides an overview of therapeutic pipeline activity for Muscle Invasive Bladder cancer across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Muscle Invasive Bladder cancer therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Muscle Invasive Bladder cancer Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Muscle Invasive Bladder cancer

Key Topics Covered:

1. Report Introduction

2. Muscle Invasive Bladder cancer

2.1. Muscle Invasive Bladder cancer Disease Overview

2.2. Muscle Invasive Bladder cancer History

2.3. Muscle Invasive Bladder cancer Symptoms

2.4. Muscle Invasive Bladder cancer Causes

2.5. Muscle Invasive Bladder cancer Pathophysiology

2.6. Muscle Invasive Bladder cancer Diagnosis

2.6.1. Diagnostic Guidelines

3. Muscle Invasive Bladder cancer Current Treatment Patterns

3.1. Treatment Guidelines

4. Muscle Invasive Bladder cancer- An Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Muscle Invasive Bladder cancer companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Muscle Invasive Bladder cancer Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Muscle Invasive Bladder cancer Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Muscle Invasive Bladder cancer Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.3. Early Stage Products (Phase-I)

5.4. Pre-clinical and Discovery Stage Products

5.5. Inactive Products

6. Muscle Invasive Bladder cancer-Products Analysis

6.1. Product Profiles

6.1.1. TAR-200- Taris Bio

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

6.1.2. Durvalumab- AstraZeneca

7. Recent Technologies

8. Muscle Invasive Bladder cancer Key Companies

8.1. AstraZeneca

8.2. Oncolytics Biotech

8.3. Medimmune

8.4. TARIS Biomedical

8.5. Bristol-Myers Squibb

9. Muscle Invasive Bladder cancer Key Products

9.1. Durvalumab

9.2. Pelareorep

9.3. AZD4547

9.4. TAR 200

9.5. Nivolumab

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Muscle Invasive Bladder cancer- Unmet Needs

12. Muscle Invasive Bladder cancer- Future Perspectives

13. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/887jho

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900